GlaxoSmithKline PLC (GSK) Shares Sold by A. D. Beadell Investment Counsel Inc.

A. D. Beadell Investment Counsel Inc. cut its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 20.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,965 shares of the pharmaceutical company’s stock after selling 6,250 shares during the quarter. A. D. Beadell Investment Counsel Inc.’s holdings in GlaxoSmithKline PLC were worth $972,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GSK. Renaissance Technologies LLC grew its position in shares of GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares during the period. FMR LLC grew its position in shares of GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after purchasing an additional 1,389,238 shares during the period. Bank of America Corp DE grew its position in shares of GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after purchasing an additional 934,928 shares during the period. Federated Investors Inc. PA grew its position in shares of GlaxoSmithKline PLC by 22.7% in the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after purchasing an additional 833,501 shares during the period. Finally, Marshall Wace North America L.P. grew its position in shares of GlaxoSmithKline PLC by 148.0% in the 2nd quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock valued at $48,138,000 after purchasing an additional 668,088 shares during the period. Institutional investors and hedge funds own 9.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/10/29/glaxosmithkline-plc-gsk-shares-sold-by-a-d-beadell-investment-counsel-inc.html.

Several equities analysts recently issued reports on GSK shares. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, July 18th. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $44.33.

GlaxoSmithKline PLC (NYSE:GSK) traded down 1.01% during trading on Friday, reaching $36.23. The company’s stock had a trading volume of 6,898,215 shares. The stock has a market cap of $88.55 billion, a PE ratio of 35.11 and a beta of 1.03. The company’s 50-day moving average is $40.27 and its 200-day moving average is $41.42. GlaxoSmithKline PLC has a 12 month low of $36.16 and a 12 month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 115.30% and a net margin of 7.79%. Equities analysts expect that GlaxoSmithKline PLC will post $2.89 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be given a dividend of $0.5037 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.56%. GlaxoSmithKline PLC’s payout ratio is presently 162.30%.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit